Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression

Jul 30, 2024, 11:14 AM

Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.